title: Respondent and item level patterns of response of aripiprazole in the acute treatment of pediatric bipolar I disorder.
abstract: BACKGROUND
  Few studies have evaluated the value of a parent- and subject-rated scale in detecting symptom change in response to pharmacologic treatment.
  
  
  METHODS
  This was a post-hoc analysis of data from a 4-week, randomized, double-blind, placebo-controlled study to evaluate which informants detect response to treatment with aripiprazole in pediatric subjects experiencing a mixed or manic episode associated with bipolar I disorder. Efficacy assessments included clinician-rated scales and the parent- and subject-rated 10-item General Behavior Inventory Mania (GBI-M10) and Depression (GBI-D10) scales. Cohen's d quantified effect sizes for total scale scores and individual line items.
  
  
  RESULTS
  Parent-GBI-M10 total, clinician-rated Young Mania Rating Scale (YMRS) total, and Clinical Global Impression-Bipolar Disorder (CGI-BP) Mania scores produced similar effect sizes, suggesting that the parent-GBI-M10 is sensitive to treatment-related improvements in manic symptoms. Aripiprazole improved a broad spectrum of parent-rated mania symptoms; six parent-GBI-M10 line item effect sizes were moderate (>0.5) in at least one of the two aripiprazole treatment arms (10 or 30 mg/day). Subject-completed GBI-M10 line item effect sizes were consistently smaller, indicating that the subjects' experience of treatment effects were less pronounced.
  
  
  CONCLUSIONS
  Study inclusion/exclusion criteria may limit generalizability of these findings.
  
  
  CONCLUSIONS
  Parent ratings of mania severity were in agreement with clinician ratings, indicating that parent-rated assessments can be valuable in detecting symptom change over the course of treatment. These data support the use of the parent-GBI-M10 as an outcome measure in research and clinical settings.
authors.affiliation: University Hospitals Case Medical Center/Case Western Reserve University, Cleveland, OH, USA. robert.findling@uhhospitals.org
authors.forename: Robert L
authors.initials: RL
authors.lastname: Findling
authors.forename: Eric A
authors.initials: EA
authors.lastname: Youngstrom
authors.forename: Joan
authors.initials: J
authors.lastname: Zhao
authors.forename: Ron
authors.initials: R
authors.lastname: Marcus
authors.forename: Candace
authors.initials: C
authors.lastname: Andersson
authors.forename: Robert
authors.initials: R
authors.lastname: McQuade
authors.forename: Raymond
authors.initials: R
authors.lastname: Mankoski
mesh_terms: D000293:Adolescent; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D000068180:Aripiprazole; D001714:Bipolar Disorder / Q000188:drug therapy* / Q000523:psychology; D002648:Child; D003863:Depression / Q000523:psychology; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D010290:Parents; D010879:Piperazines / Q000627:therapeutic use*; D011569:Psychiatric Status Rating Scales; D015363:Quinolones / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D014150:Antipsychotic Agents; D010879:Piperazines; D015363:Quinolones; D000068180:Aripiprazole